期刊文献+

氨氯地平片联合硝苯地平缓释片治疗妊娠期高血压患者的临床研究 被引量:37

Clinical trial of amlodipine tablets combined with nifedipine sustained release tablets in the treatment of hypertensive patients during pregnancy
原文传递
导出
摘要 目的观察氨氯地平片联合硝苯地平缓释片治疗妊娠期高血压患者的临床疗效及安全性。方法将165例妊娠期高血压患者随机分为对照A组62例、对照B组58例和试验组45例。对照A组给予氨氯地平片每次10 mg,qd,口服;对照B组给予硝苯地平缓释片每次10 mg,bid,口服;试验组给予氨氯地平片每次5 mg,qd,口服+硝苯地平缓释片每次10 mg,qd,口服。3组患者均治疗7 d。比较3组患者的临床疗效,血压,以及药物不良反应的发生情况。结果治疗后,试验组、对照A组和对照B组的总有效率分别为93.33%(42例/45例),77.42%(48例/62例)和72.41%(42例/58例),试验组的总有效率与对照A组和对照B组比较,差异均有统计学意义(均P<0.05)。治疗后,试验组、对照A组和对照B组的收缩压分别为(114.15±10.60),(131.35±11.38)和(131.75±10.67)mmHg,舒张压分别为(80.88±5.21),(93.31±4.94)和(94.36±3.95)mmHg,试验组的上述指标与对照A组和对照B组比较,差异均有统计学意义(均P<0.05)。试验组发生的药物不良反应主要有头痛和水肿,对照A组的药物不良反应主要有头昏和乏力,对照B组的药物不良反应主要有头痛和面部潮红。试验组、对照A组和对照B组的总药物不良反应发生率分别为6.66%,8.06%和8.62%,两两比较,差异均无统计学意义(均P>0.05)。结论氨氯地平片联合硝苯地平缓释片治疗妊娠期高血压患者的临床疗效显著,其能有效地改善患者血压,且不增加药物不良反应的发生率。 Objective To observe the clinical efficacy and safety of amlodipine tablets combined with nifedipine sustained release tablets in the treatment of hypertensive patients during pregnancy. Methods A total of 165 hypertensive patients during pregnancy were randomly divided into control A group(n=62 cases), control B group(n=58 cases) and treatment group(n=45 cases). Control A group was given amlodipine tablets 10 mg per time, qd, orally. Control B group was given nifedipine sustained release tablets 10 mg per time, bid, orally. Treatment group was given amlodipine tablets 5 mg per time, qd, orally + nifedipine sustained release tablets 10 mg per time, qd, orally. Three groups were treated for 7 days. The clinical efficacy, blood pressure and adverse drug reactions were compared among three groups. Results After treatment, the total effective rates of treatment, control A and control B groups were 93. 33%( 42 cases/45 cases),77. 42%( 48 cases/62 cases) and 72. 41%( 42 cases/58 cases),there were statistically significant differences between treatment group and control A and control B groups( all P < 0. 05). After treatment, the systolic blood pressure of the treatment group, control A group and control B group were( 114. 15 ± 10. 60),( 131. 35 ± 11. 38) and( 131. 75 ± 10. 67) mm Hg, the diastolic blood pressure were( 80. 88 ± 5. 21),( 93. 31 ± 4. 94) and( 94. 36 ± 3. 95) mm Hg,there were statistically significant differences between treatment group and control A and control B groups( all P < 0. 05). The adverse drug reactions of treatment group were headache and edema. The adverse drug reactions of control A group were dizziness and fatigue. The adverse drug reactions of control B group were headache and facial flushing. The total incidences of adverse drug reactions in treatment,control A and control B groups were 6. 66%,8. 06% and 8. 62% without significant differences( all P≥0. 05). Conclusion Amlodipine tablets combined with nifedipine sustained-release tablets have significant clinical efficacy in the treatment of pregnant patients with hypertension,which can significantly improve the patients’ blood pressure,without increasing the incidence of adverse drug reactions.
作者 赵飞飞 艾芳 吴婕 党彦丽 ZHAO Fei-fei;AI Fang;WU Jie;DANG Yan-li(Department of Obstetrics,The First People's Hospital of Yunnan Province/Affiliated Hospital of Kunming University of Technology,Kunming 650032,Yunnan Province,China)
出处 《中国临床药理学杂志》 CAS CSCD 北大核心 2021年第11期1315-1317,1321,共4页 The Chinese Journal of Clinical Pharmacology
基金 云南省卫生科技计划基金资助项目(2017NS219) 云南省科技厅科技计划基金资助项目(2018FE001-118)。
关键词 氨氯地平片 硝苯地平缓释片 妊娠期高血压 安全性评价 amlodipine tablet nifedipine sustained release tablet gestational hypertension safety evaluation
  • 相关文献

参考文献6

二级参考文献77

  • 1Li Wang,Zhi-Qiang Liu,Ying-Qian Huo,Li-Juan Yao,Xue-Gong Wei,Yun-Fang Wang.Change of hs-CRP,sVCAM-1,NT-proBNP levels in patients with pregnancy-induced hypertension after therapy with magnesium sulfate and nifudipine[J].Asian Pacific Journal of Tropical Medicine,2013,6(11):897-901. 被引量:46
  • 2American College of Obstetricians and Gynecologists;Task Force on Hypertension in Pregnancy.Hypertension in pregnancy.Report of the American College of Obstetricians and Gynecologists' Task Force on Hypertension in Pregnancy[J].Obstet Gynecol,2013,122(5):1122-1131.DOI:10.1097/01.AOG.0000437382.03963.88.
  • 3Magee LA,Pels A,Helewa M,et al.Canadian Hypertensive Disorders of Pregnancy Working Group.Diagnosis,evaluation,and management of the hypertensive disorders of pregnancy:executive summary[J].J Obstet Gynaecol Can,2014,36(5):416 441.
  • 4Visintin C,Mugglestone MA,Almerie MQ,et al.Management of hypertensive disorders during pregnancy:summary of NICE guidance[J].BMJ,2010,341:c2207.DOI:10.1136/bmj.c2207.
  • 5Lowe SA,Bowyer L,Lust K,et al.The SOMANZ Guidelines for the Management of Hypertensive Disorders of Pregnancy 2014[J].Aust N Z J Obstet Gynaecol,2015,55(1):11-16.DOI:10.1111/ajo.12253.
  • 6Campos-Outcalt D Sr.US Preventive Services Task Force:the gold standard of evidence-based prevention[J].J Fam Pract,2005,54(6):517-519.
  • 7Magee LA,Helewa M,Moutquin JM,et al.Diagnosis,evaluation,and management of the hypertensive disorders of pregnancy[J].J Obstet Gynaceol Can,2008,30(3 Suppl):S 1-48.
  • 8C(o)té AM,Brown MA,Lam E,et al.Diagnostic accuracy of urinary spot protein:creatinine ratio for proteinuria in hypertensive pregnant women:systematic review[J].BMJ,2008,336(7651):1003-1006.DOI:10.1136/bmj.39532.543947.BE.
  • 9Churchill D,Beevers GD,Meher S,et al.Diuretics for preventing pre-eclampsia[J].Cochrane Database Syst Rev,2007(1):CD004451.
  • 10McCoy S,Baldwin K.Pharmacotherapeutic options for the treatment of preeclampsia[J].Am J Health Syst Pharm,2009,66(4):337-344.DOI:10.2146/ajhp080104.

共引文献400

同被引文献344

引证文献37

二级引证文献83

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部